A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

Tioga Medical, A Shifamed Portfolio Company, Closes $30M In Series B Financing

Tioga Medical, Inc., a Shifamed portfolio company that aims to redefine structural heart valve replacement, announced today the initial closing of its committed $30M Series B financing. Led by The Capital Partnership (TCP), with participation from Cormorant Asset Management, AMED Ventures, and Shifamed angel investors, the financing will be used to advance product development, support pre-clinical testing, and initiate clinical experience for the company’s novel transcatheter valve replacement technology.

“Current valve replacement approaches are either surgically invasive, anatomically limited, or procedurally complex, hindering use despite the significant clinical need. Tioga’s proprietary technology aims to address these challenges with a less invasive, more adaptable transcatheter intervention,” commented Gautam Kainth, Managing Director at TCP. “We are pleased to lead this round and look forward to delivering this much-needed solution to this large and underserved segment of the structural heart market.”

Mitral valve disease is the company’s initial focus and is the largest structural heart valve problem, roughly four times more common than aortic stenosis.1,2 Directly tied to heart failure, mitral valve disease can increase cardiac workload and is associated with increased morbidity and mortality. Current surgical approaches are invasive and not widely utilized, leaving many patients undertreated. Similar to the recent adoption for transcatheter aortic valve replacement (TAVR), there is a significant clinical need for less invasive, transcatheter approaches for mitral valve replacement.

“We are extremely pleased to close this round of financing with strong, continued support from our investors, validating the clear unmet need in this space,” stated Mike Dineen, President and CEO of Tioga Medical. “We look forward to furthering our development efforts and demonstrating the performance of Tioga’s next-generation design to simplify and improve the safety and efficacy of transcatheter valve replacement procedures for both physicians and patients.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Noze states the grant will fund a groundbreaking clinical study aimed at detecting TB in high-burden countries, using the company's DiagNoze® — a handheld breathalyzer designed for the real-time detection and screening of various medical conditions, including infectious diseases such as TB.
Research teams led by a faculty member in Purdue University’s College of Engineering will use two grants from the National Eye Institute totaling $6.7 million to further develop specialized smart soft contact lenses that continuously monitor or treat chronic ocular diseases like glaucoma, corneal neovascularization and dry eye syndromes.
The series B funding round saw participation from venture capital firms Blume Ventures, Steadview Capital, Nexus Venture Partners, Alpha Wave and Zomato founder Deepinder Goyal. Ultrahuman will deploy the funds towards building further manufacturing capacity and deeper research in the health tracking space notes Ultrahuman.
Bone Health Technologies Bone Health Technologies (BHT), a health technology innovator developing breakthrough non-invasive solutions for bone health, today announced the company has raised a...
Howard Robin, President and Chief Executive Officer of Nektar Therapeutics: "We are pleased to bring on TCGX as a new high-quality, long-term investor in Nektar as we advance rezpegaldesleukin through our Phase 2b studies in atopic dermatitis and alopecia areata. We are on track to report topline data from these studies in the first half of 2025, which will represent significant inflection points for Nektar. Today's financing further bolsters our financial position and extends the company's cash runway well into the third quarter of 2026."

By using this website you agree to accept Medical Device News Magazine Privacy Policy